The current financial score of Organogenesis Holdings Inc is 7.42. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 43.76M, representing a year-over-year decrease of 56.68%, while its net profit experienced a year-over-year decrease of 714.12%.
The current valuation score of Organogenesis Holdings Inc is 7.93. Its current P/E ratio is -12.85, which is -1027.28% below the recent high of 119.16 and -6687.11% above the recent low of -872.19.
The current earnings forecast score of Organogenesis Holdings Inc is 6.00. The average price target is 2.00, with a high of 2.00 and a low of 2.00.
The current price momentum score of Organogenesis Holdings Inc is 5.88. Currently, the stock price is trading between the resistance level at 1.75 and the support level at 1.22, making it suitable for range-bound swing trading.
The current institutional shareholding score of Organogenesis Holdings Inc is 5.00. The latest institutional shareholding proportion is 55.15%, representing a quarter-over-quarter increase of 0.09%. The largest institutional shareholder is James Simons, holding a total of 1.02M shares, representing 0.00% of shares outstanding, with 50.11% decrease in holdings.
The current risk assessment score of Organogenesis Holdings Inc is 3.47. The company's beta value is 1.32. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.